Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin.
Dual and triple infections with hepatitis virus C (HCV), B (HBV) and D (HDV) frequently lead to severe liver damage. Hereby we describe a 38-year-old Caucasian male coinfected with HCV (genotype 3a), HBV [positive hepatitis B surface antigen (HbsAg) and antibody to hepatitis B core antigen; negative hepatitis B e antigen (HbeAg) and antibody to hepatitis B e antigen (anti-HBe)] and HDV. Laboratory diagnostics revealed increased liver enzymes and histological examination of the liver showed signs of fibrosis with moderate inflammation. On therapy with pegIFN-α2b and ribavirin HCV-RNA was undetectable at week 8. After week 24 the antiviral therapy was stopped because of a HBs-seroconversion, the loss of HbeAg and the detection of anti-HBe. Furthermore the HCV-RNA was negative. Six months after successful treatment of the triple-infection, HCV- and HDV-RNA and HbsAg remained negative and the liver enzymes had been completely normalized. In conclusion, pegylated-interferon plus ribavirin may be an effective therapy for HCV, HBV and HDV-coinfected patients.
Internal Medicine 1, University Hospital of Regensburg, Germany.
Janine
J
Hartl
Internal Medicine 1, University Hospital of Regensburg, Germany.
Claudia
C
Ott
Internal Medicine 1, University Hospital of Regensburg, Germany.
Gabriele
G
Kirchner
Internal Medicine 1, University Hospital of Regensburg, Germany.
Bernd
B
Salzberger
Internal Medicine 1, University Hospital of Regensburg, Germany.
Reiner
R
Wiest
HBV; HCV; HDV; pegylated interferon; ribavirin.; triple-hepatitis